Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement

Published: Apr 08, 2009

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 contained an unqualified audit opinion from its independent public accounting firm, Ernst & Young LLP, which included a “going concern” explanatory statement. This disclosure is required under NASDAQ rules and does not represent any change to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 which was filed on March 31, 2009 with the Securities and Exchange Commission.

Back to news